FRANKLIN LAKES, N.J., Aug. 15, 2011 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company), today announced the launch of the BD Emerald™ Syringe portfolio designed to meet emerging needs in medication delivery while addressing environmental impact by reducing material. The BD Emerald Syringe portfolio includes the BD Emerald™ Conventional Syringe for general medication preparation and delivery, the BD Emerald Saf-T™ Syringe with a shielding mechanism to protect against needlesticks and the BD Emerald PRO™ Reuse Prevention Syringe featuring a passive locking system to prevent reuse.
The BD Emerald product family is designed sustainably with input from clinicians around the world. The product family is also supported by the Company's long-standing history and commitment to developing first-class injection devices supported by clinical education programs to improve the delivery of healthcare. The BD Emerald Syringes will be manufactured at facilities in Spain, India and Brazil, utilizing sustainable manufacturing practices, including 100 percent renewable electricity for production where available. The syringes meet the International Organization and Standardization requirements, and satisfy local registration standards.
“BD recognizes that human health and a healthy environment are inseparable,” said Bill Kozy, Executive Vice President, BD. “We are committed to responsible environmental stewardship in our business conduct. The BD Emerald Syringes meet our highest standards for product quality while also reducing environmental impact by using sustainable operations practices and less material.”
The BD Emerald Syringe family offers features to prevent the spread of infection, address environmental impact, address clinical needs and meet quality standards around the world:
- BD Emerald Saf-T Syringe is designed to address the needs